1. DNA base oxidation in relation to TNM stages and chemotherapy treatment in colorectal cancer patients 2–9 months post-surgery.
- Author
-
Nordengen, Anne Lene, Kværner, Ane S., Krutto, Annika, Alavi, Dena T., Henriksen, Hege B., Henriksen, Christine, Raastad, Truls, Smeland, Sigbjørn, Bøhn, Siv K., Shaposhnikov, Sergey, Collins, Andrew R., and Blomhoff, Rune
- Subjects
- *
IRINOTECAN , *COLORECTAL cancer , *MONONUCLEAR leukocytes , *CANCER patients , *RECTAL cancer , *CANCER treatment - Abstract
Accumulation of DNA damage is a critical feature of genomic instability, which is a hallmark of various cancers. The enzyme-modified comet assay is a recognized method to detect specific DNA lesions at the level of individual cells. In this cross-sectional investigation, we explore possible links between clinicopathological and treatment related factors, nutritional status, physical activity and function, and DNA damage in a cohort of colorectal cancer (CRC) patients with non-metastatic disease. Levels of DNA damage in peripheral mononuclear blood cells (PBMCs) assessed 2–9 months post-surgery, were compared across tumour stage (localized (stage I-II) vs. regional (stage III) disease), localization (colon vs. rectosigmoid/rectum cancer), and adjuvant chemotherapy usage, with the last dosage administrated 2–191 days prior to sampling. Associations between DNA damage and indicators of nutritional status, physical activity and function were also explored. In PBMCs, DNA base oxidation was higher in patients diagnosed with regional compared with localized tumours (P = 0.03), but no difference was seen for DNA strand breaks (P > 0.05). Number of days since last chemotherapy dosage was negatively associated with DNA base oxidation (P < 0.01), and patients recently receiving chemotherapy (<15 days before blood collection) had higher levels of DNA base oxidation than those not receiving chemotherapy (P = 0.03). In the chemotherapy group, higher fat mass (in kg and %) as well as lower physical activity were associated with greater DNA base oxidation (P < 0.05). In conclusion, DNA base oxidation measured with the enzyme-modified comet assay varies according to tumour and lifestyle related factors in CRC patients treated for non-metastatic disease. [Display omitted] • DNA base oxidation varies in non-metastatic colorectal cancer remission. • High levels potentially affect prognosis and the risk of long-term side effects. • Enzyme-modified comet assay serve as a valuable biomarker for DNA base oxidation. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF